Developer docs
API playgroundTry for free, no card

Search company profiles

NonExomics

Full company profile

uuid0002gsf

Namestring
NonExomics
Legal namestring
NonExomics, Inc.
Websiteurl
nonexomics.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

NonExomics, Inc. is a medicinal genomics company that has built an 8+ year, cloud-deployed machine-learning platform integrating genomics, transcriptomics, proteomics, structural genomics, and biochemical/biophysical methodologies to discover and validate noncanonical proteins — proteins it claims are generated from the entire human genome rather than just the canonical 1–2% gene region. The platform has reportedly validated under 250,000 noncanonical proteins and identified under 3,000 novel drug targets associated with 1,365 human diseases, with experimental validation of druggability across multiple targets using modalities including small molecules, antisense oligos, antibodies, and gene therapy.

The company monetizes through a partnership-driven model: it licenses its noncanonical protein target portfolio to pharma and biotech for drug development, runs collaborative target-identification and validation services for biotech, pharma, and academic clients, and offers companion-diagnostics co-development for rare-disease and oncology patient stratification. Pricing is bespoke and not publicly disclosed; the distribution channel is direct enterprise sales of collaboration agreements, supported by scientific publications and earned media rather than traditional marketing.

NonExomics was founded in 2016 as NonExomics, LLC by Ruchi Chauhan and Sudhakaran Prabakaran (later joined by serial bio-instrumentation entrepreneur Gary Magnant) and reincorporated in 2021 as NonExomics, Inc. The company is headquartered in Boston, with operations in Cambridge, UK (where Prabakaran ran an academic lab from 2016 to 2021) and indicated activity in India. It is privately held, venture-backed, employs 1–10 people, and is currently in early-stage commercialization with only a pre-seed round and an Illumina Accelerator investment disclosed to date.

Short descriptiontext

NonExomics is a privately held medicinal genomics company that uses a cloud-deployed machine-learning platform integrating multi-omics data to discover noncanonical protein drug targets across 1,365 human diseases, serving pharmaceutical, biotech, and academic clients via licensing and collaboration agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBeverly, United States
HQ citystring
Beverly
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug target discovery, noncanonical proteins, dark genome analysis, medicinal genomics, multi-omics integration
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Drug Target Discovery / Medicinal Genomics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Target Licensing and Partnership Deals
TypeLicensing Royalties
Description

NonExomics generates revenue by licensing their discovered noncanonical protein targets to pharmaceutical and biotech companies for drug development. The company seeks partnerships to advance treatments through clinical trials.

nonexomics.com
2Target Identification Services
TypeProfessional Services
Description

Collaborative services for biotech companies, pharmaceutical companies, and academia to identify disease-specific targets using the NonExomics platform. Targets are validated experimentally for further preclinical validations.

nonexomics.com
3Companion Diagnostics Development
TypeProfessional Services
Description

Partnership opportunities for companion diagnostics identification in drug co-development process, including diagnosis and patient stratification for rare diseases and cancer.

nonexomics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NonExomics develops a proprietary, patent-pending machine learning platform that integrates genomics, transcriptomics, proteomics, and structural biology to identify druggable noncanonical proteins from the entire human genome. The company sells target identification services, licensing of novel drug targets, and companion diagnostics collaboration to pharmaceutical companies, biotech firms, and academic institutions. Its portfolio includes under 3,000 novel targets associated with 1,365 human diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Demonstrated that 10x more proteins exist than previously known, enabling understanding of difficult-to-treat diseases
+2 more records
Product overview1 text field

NonExomics operates as a medicinal genomics company with a unified platform approach centered on decoding the dark genome. The core NonExomics Dark Genome Analysis Platform integrates genomics, transcriptomics, proteomics, and AI methodologies to identify druggable noncanonical proteins from the entire human genome. This platform is supported by three complementary service offerings: Target Identification Services for disease-specific collaboration, Therapeutic Modality Collaboration for validating targets across small molecules, antisense oligos, antibodies, and gene therapy, and Companion Diagnostics for patient stratification and drug co-development. Together, these services address a portfolio of approximately 3000 novel targets associated with 1365 human diseases.

Product and service4 records
1NonExomics Dark Genome Analysis Platform
CategoryGenomics Platform / Core Technology
Description

A proprietary and patent-pending platform that integrates genomics, transcriptomics, proteomics, and AI methodologies to identify druggable noncanonical proteins from the entire human genome, including the 98% previously considered non-coding.

2Target Identification Services
CategoryDrug Discovery Services
Description

Collaborative service with biotech companies, pharmaceutical companies, and academia to identify disease-specific targets using the NonExomics platform, with experimental validation for preclinical studies.

3Therapeutic Modality Collaboration
CategoryDrug Discovery Services
Description

Partner engagement offering to validate prioritized targets using small molecules, antisense oligos, antibodies, and gene therapy approaches.

4Companion Diagnostics
CategoryDiagnostics Development Services
Description

Discovery service to identify companion diagnostics for drug co-development, including patient diagnosis and stratification for rare diseases and cancer.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NonExomics originated from research conducted at the University of Cambridge. Co-founder Sudhakaran Prabakaran ran his academic lab in the Department of Genetics at Cambridge. The company licensed dark genome research from Cambridge and continues academic collaborations.

2Undisclosed Partner Organizations
Strategic tierMinorTypeStrategic or Co-development Partner
Description

NonExomics has forged two undisclosed partnerships for target validation and preclinical development. The company is actively seeking additional partnership opportunities.

nonexomics.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion is an AI-driven drug-discovery platform that integrates high-throughput biology with machine learning to identify novel therapeutic targets and develop small-molecule candidates. It is directly comparable to NonExomics in using ML + multi-omics to expand the target universe, though Recursion focuses on phenotypic screening rather than noncanonical proteins.

TypeDirect peer
Description

Insitro combines machine learning with functional genomics and induced pluripotent stem cell biology to discover and validate novel drug targets. Like NonExomics, it positions itself as a target-discovery platform selling partnerships to pharma, and competes for the same ML-multi-omics-capital narrative.

TypeDirect peer
Description

Schrödinger operates a computational chemistry and biology platform used by pharma to discover targets and design molecules, with a software-plus-services business model. It is comparable to NonExomics as a platform selling computational discovery into pharma pipelines, though at a far more mature stage.

TypeDirect peer
Description

Verge uses ML on human multi-omics data — including genomics and transcriptomics from patient tissue — to identify new therapeutic targets, with an emphasis on neuroscience. It directly parallels NonExomics' ML + multi-omics approach and its emphasis on difficult-to-treat neurological disease.

TypeDirect peer
Description

BenevolentAI applies AI to biomedical knowledge graphs and omics data to identify novel targets and reposition existing drugs. It is comparable to NonExomics as an AI-driven target-identification partner for pharma, particularly in complex diseases where traditional target discovery has underperformed.

TypeDirect peer
Description

Owkin is an AI-biotech that uses multimodal patient data (genomics, transcriptomics, histology) to discover biomarkers, targets, and companion diagnostics, often partnering with academic medical centers. Its data-driven target and CDx discovery model closely resembles NonExomics' target identification + companion diagnostics offering.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) is a leading molecular diagnostics and companion-diagnostics company whose genomics platform identifies patient-specific alterations to guide therapy selection. It is comparable to NonExomics as a CDx and genomic-target-discovery player, but at much greater scale and with established pharma partnerships.

TypeBroad incumbent
Description

10x Genomics provides single-cell and spatial omics instrumentation and consumables used widely in target-discovery and translational research workflows. It is comparable as an enabling technology provider in the multi-omics discovery stack that NonExomics' platform depends on, though it sells tools rather than targets.

TypeBroad incumbent
Description

SomaLogic operates a large-scale proteomics platform (SomaScan) measuring thousands of proteins for biomarker and target discovery, partnering with pharma and academic researchers. It is comparable to NonExomics in scaling proteomic measurement for novel protein target identification, though SomaLogic focuses on known-protein quantification rather than noncanonical discovery.

TypeBroad incumbent
Description

Exscientia is an AI-driven precision medicine company combining target identification with end-to-end small-molecule drug design. It is comparable to NonExomics as a pharma-partnered AI drug-discovery platform, though Exscientia is more advanced in clinical assets and platform commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NonExomics

Drug Target Discovery / Medicinal Genomicsnonexomics.com

NonExomics is a privately held medicinal genomics company that uses a cloud-deployed machine-learning platform integrating multi-omics data to discover noncanonical protein drug targets across 1,365 human diseases, serving pharmaceutical, biotech, and academic clients via licensing and collaboration agreements.

What NonExomics does

NonExomics, Inc. is a medicinal genomics company that has built an 8+ year, cloud-deployed machine-learning platform integrating genomics, transcriptomics, proteomics, structural genomics, and biochemical/biophysical methodologies to discover and validate noncanonical proteins — proteins it claims are generated from the entire human genome rather than just the canonical 1–2% gene region. The platform has reportedly validated under 250,000 noncanonical proteins and identified under 3,000 novel drug targets associated with 1,365 human diseases, with experimental validation of druggability across multiple targets using modalities including small molecules, antisense oligos, antibodies, and gene therapy.

The company monetizes through a partnership-driven model: it licenses its noncanonical protein target portfolio to pharma and biotech for drug development, runs collaborative target-identification and validation services for biotech, pharma, and academic clients, and offers companion-diagnostics co-development for rare-disease and oncology patient stratification. Pricing is bespoke and not publicly disclosed; the distribution channel is direct enterprise sales of collaboration agreements, supported by scientific publications and earned media rather than traditional marketing.

NonExomics was founded in 2016 as NonExomics, LLC by Ruchi Chauhan and Sudhakaran Prabakaran (later joined by serial bio-instrumentation entrepreneur Gary Magnant) and reincorporated in 2021 as NonExomics, Inc. The company is headquartered in Boston, with operations in Cambridge, UK (where Prabakaran ran an academic lab from 2016 to 2021) and indicated activity in India. It is privately held, venture-backed, employs 1–10 people, and is currently in early-stage commercialization with only a pre-seed round and an Illumina Accelerator investment disclosed to date.

NonExomics firmographics

Firmographics
Name
NonExomics
Legal name
NonExomics, Inc.
Website
https://nonexomics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
NonExomics is a privately held medicinal genomics company that uses a cloud-deployed machine-learning platform integrating multi-omics data to discover noncanonical protein drug targets across 1,365 human diseases, serving pharmaceutical, biotech, and academic clients via licensing and collaboration agreements.
Ownership category
akta.pro rank

NonExomics industry classification

Industry
Product category
Drug Target Discovery / Medicinal Genomics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Drug target discovery
  • Noncanonical proteins
  • Dark genome analysis
  • Medicinal genomics
  • Multi-omics integration

Where NonExomics is headquartered

Location

Headquarters

HQ city
Beverly
HQ country
United States
HQ region
North America

Offices3 records

Markets served

NonExomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Target Licensing and Partnership Deals: NonExomics generates revenue by licensing their discovered noncanonical protein targets to pharmaceutical and biotech companies for drug development. The company seeks partnerships to advance treatments through clinical trials.
  2. Target Identification Services: Collaborative services for biotech companies, pharmaceutical companies, and academia to identify disease-specific targets using the NonExomics platform. Targets are validated experimentally for further preclinical validations.
  3. Companion Diagnostics Development: Partnership opportunities for companion diagnostics identification in drug co-development process, including diagnosis and patient stratification for rare diseases and cancer.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NonExomics product offering

Product offering

Core offering

NonExomics develops a proprietary, patent-pending machine learning platform that integrates genomics, transcriptomics, proteomics, and structural biology to identify druggable noncanonical proteins from the entire human genome. The company sells target identification services, licensing of novel drug targets, and companion diagnostics collaboration to pharmaceutical companies, biotech firms, and academic institutions. Its portfolio includes under 3,000 novel targets associated with 1,365 human diseases.

Product overview

NonExomics operates as a medicinal genomics company with a unified platform approach centered on decoding the dark genome. The core NonExomics Dark Genome Analysis Platform integrates genomics, transcriptomics, proteomics, and AI methodologies to identify druggable noncanonical proteins from the entire human genome. This platform is supported by three complementary service offerings: Target Identification Services for disease-specific collaboration, Therapeutic Modality Collaboration for validating targets across small molecules, antisense oligos, antibodies, and gene therapy, and Companion Diagnostics for patient stratification and drug co-development. Together, these services address a portfolio of approximately 3000 novel targets associated with 1365 human diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • NonExomics Dark Genome Analysis Platform A proprietary and patent-pending platform that integrates genomics, transcriptomics, proteomics, and AI methodologies to identify druggable noncanonical proteins from the entire human genome, including the 98% previously considered non-coding.
  • Target Identification Services Collaborative service with biotech companies, pharmaceutical companies, and academia to identify disease-specific targets using the NonExomics platform, with experimental validation for preclinical studies.
  • Therapeutic Modality Collaboration Partner engagement offering to validate prioritized targets using small molecules, antisense oligos, antibodies, and gene therapy approaches.
  • Companion Diagnostics Discovery service to identify companion diagnostics for drug co-development, including patient diagnosis and stratification for rare diseases and cancer.

Quantifiable outcome

  • Demonstrated that 10x more proteins exist than previously known, enabling understanding of difficult-to-treat diseases
  • +2 more outcomes

Companies that use NonExomics

Customer profile

Segments4 records

Ideal customer profiles4 records

NonExomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

NonExomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • University of CambridgecoreStrategic or Co-development PartnerNonExomics originated from research conducted at the University of Cambridge. Co-founder Sudhakaran Prabakaran ran his academic lab in the Department of Genetics at Cambridge. The company licensed dark genome research from Cambridge and continues academic collaborations.
  • Undisclosed Partner OrganizationsminorStrategic or Co-development PartnerNonExomics has forged two undisclosed partnerships for target validation and preclinical development. The company is actively seeking additional partnership opportunities.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

NonExomics competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion is an AI-driven drug-discovery platform that integrates high-throughput biology with machine learning to identify novel therapeutic targets and develop small-molecule candidates. It is directly comparable to NonExomics in using ML + multi-omics to expand the target universe, though Recursion focuses on phenotypic screening rather than noncanonical proteins.
  • Insitro: Insitro combines machine learning with functional genomics and induced pluripotent stem cell biology to discover and validate novel drug targets. Like NonExomics, it positions itself as a target-discovery platform selling partnerships to pharma, and competes for the same ML-multi-omics-capital narrative.
  • Schrödinger: Schrödinger operates a computational chemistry and biology platform used by pharma to discover targets and design molecules, with a software-plus-services business model. It is comparable to NonExomics as a platform selling computational discovery into pharma pipelines, though at a far more mature stage.
  • Verge Genomics: Verge uses ML on human multi-omics data — including genomics and transcriptomics from patient tissue — to identify new therapeutic targets, with an emphasis on neuroscience. It directly parallels NonExomics' ML + multi-omics approach and its emphasis on difficult-to-treat neurological disease.
  • BenevolentAI: BenevolentAI applies AI to biomedical knowledge graphs and omics data to identify novel targets and reposition existing drugs. It is comparable to NonExomics as an AI-driven target-identification partner for pharma, particularly in complex diseases where traditional target discovery has underperformed.
  • Owkin: Owkin is an AI-biotech that uses multimodal patient data (genomics, transcriptomics, histology) to discover biomarkers, targets, and companion diagnostics, often partnering with academic medical centers. Its data-driven target and CDx discovery model closely resembles NonExomics' target identification + companion diagnostics offering.

Broad incumbents

  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading molecular diagnostics and companion-diagnostics company whose genomics platform identifies patient-specific alterations to guide therapy selection. It is comparable to NonExomics as a CDx and genomic-target-discovery player, but at much greater scale and with established pharma partnerships.
  • 10x Genomics: 10x Genomics provides single-cell and spatial omics instrumentation and consumables used widely in target-discovery and translational research workflows. It is comparable as an enabling technology provider in the multi-omics discovery stack that NonExomics' platform depends on, though it sells tools rather than targets.
  • SomaLogic: SomaLogic operates a large-scale proteomics platform (SomaScan) measuring thousands of proteins for biomarker and target discovery, partnering with pharma and academic researchers. It is comparable to NonExomics in scaling proteomic measurement for novel protein target identification, though SomaLogic focuses on known-protein quantification rather than noncanonical discovery.
  • Exscientia: Exscientia is an AI-driven precision medicine company combining target identification with end-to-end small-molecule drug design. It is comparable to NonExomics as a pharma-partnered AI drug-discovery platform, though Exscientia is more advanced in clinical assets and platform commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

NonExomics social profiles

Digital presence

NonExomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NonExomics leadership team

Management profile

Number of profiles

Profiles3 records

NonExomics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NonExomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NonExomics

What does NonExomics do?

NonExomics develops a proprietary, patent-pending machine learning platform that integrates genomics, transcriptomics, proteomics, and structural biology to identify druggable noncanonical proteins from the entire human genome. The company sells target identification services, licensing of novel drug targets, and companion diagnostics collaboration to pharmaceutical companies, biotech firms, and academic institutions. Its portfolio includes under 3,000 novel targets associated with 1,365 human diseases.

Is NonExomics a public or private company?

NonExomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was NonExomics founded?

NonExomics was founded in 2016. It employs 1 to 10 people.

Where is NonExomics based?

NonExomics is headquartered in Beverly, United States, in the North America region.

How does NonExomics make money?

Three revenue lines are on record. Target Licensing and Partnership Deals are the primary driver. The others are target Identification Services and companion Diagnostics Development.

Who are NonExomics's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Verge Genomics, BenevolentAI and Owkin. Broad incumbents are Foundation Medicine, 10x Genomics, SomaLogic and Exscientia.

Does NonExomics have an API?

No public API is recorded for NonExomics.

What industry is NonExomics in?

NonExomics's product category is Drug Target Discovery / Medicinal Genomics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals